Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China, US Carve Own Paths But Physicians Urge Collaboration With Vaccines Years Away

Global Health Rivalry Or Partnerships?

Executive Summary

Despite different approaches, top virologists and renowned front-line physicians from China and the US see the need to share clinical experiences and for global cooperation on treatments and vaccines as economies start re-opening amid fear of a second wave. 

You may also be interested in...



Coronavirus Update: Rapid Japan Approval For Remdesivir, Combination With Lilly's Olumiant Is Next Hope

Plus: Chugai enters into Singapore research alliance, Korean consortium reports vaccine progress.

China Approves First Coronavirus Drugs, Rushes Two Vaccine Trials

A coronavirus vaccine race is on in China with three domestic developers leading the charge, while traditional medicines are pioneering the drug race after the first official approvals of treatments for COVID-19.

China's New Hong Kong Security Law To Derail Biotech IPOs?

A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132353

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel